logo

Nantkwest, Inc. (NK)



Trade NK now with
  Date
  Headline
12/21/2020 6:12:23 AM ImmunityBio Announces Primary Endpoint Met Of Pivotal Phase 2/3 Trial
12/21/2020 6:08:27 AM ImmunityBio And NantKwest Enter Agreement To Merge In Stock-for-stock Transaction
12/10/2020 11:06:04 PM ImmunityBio's HAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection Of Airways In Non-Human Primates
11/23/2020 9:12:34 AM ImmunityBio : Preclinical Data Shows IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
10/21/2020 5:16:43 PM ImmunityBio And NantKwest Announce First Patient Dosed In Phase 1 Clinical Trial Of HAd5-COVID-19
10/15/2020 6:03:25 AM ImmunityBio: FDA Authorizes To Begin Phase I Clinical Trial Of HAd5-COVID-19
9/10/2020 9:14:33 AM Brink Biologics Announces License Agreement With Fresenius Kabi SwissBioSim GmbH
8/24/2020 9:04:51 AM NantKwest, ImmunityBio Sign Deal For Joint Development, Commercialization Of COVID-19 Vaccine And Related Therapeutics
8/10/2020 7:28:18 AM CBR By Generate Life Sciences And NantKwest To Develop COVID-19 Treatment Leveraging Newborn Stem Cells
6/25/2020 1:04:34 AM NantKwest Announces Pricing Of Public Offering Of 7.41 Mln Shares